Special Issue

Gastrointestinal Cancers and Personalized Medicine

Message from the Guest Editors

Gastrointestinal cancers, such as esophageal and gastric cancers, pancreatic cancers, hepatobiliary cancers, colorectal cancers and gastrointestinal stromal tumors, are frequently diagnosed at an advanced stage and have a dismal prognosis. A number of biomarkers currently guide treatment decisions for patients with gastrointestinal neoplasms.

Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to "personalized cancer medicine".

The aim of this Special Issue is to provide an overview of exciting new research in the area of gastrointestinal tumours that may establish the stage for an innovative personalized management and precision medicine modalities for individualized care.

We are soliciting basic, original, translational, and clinical papers on personalized medicine in all gastrointestinal cancers, especially focusing on diagnostic and prognostic biomarkers as well as novel drug targets or targeted treatments, including eventual clinical trials.

Guest Editors

Prof. Dr. Enrico Mini

Department of Health Sciences, Universita degli Studi di Firenze, Florence, Italy

Dr. Stefania Nobili

Department of Neurosciences, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy

Deadline for manuscript submissions

closed (15 June 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/53228

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

